Fatal fulminant hepatitis following administration of clarithromycin in a patient chronically treated with antipsycotic drugs

References

• Sood GK. Acute liver failure. Update Mar 29, 2011. [http://emedicine.medscape.com/article/177354-overview].
   Google Scholar
• Navarro, V.J., Senior, J.R. Drug-related hepatotoxicity. N Engl J Med 2006, 354, 731–739.
   PubMed Web of Science ®Google Scholar
• Rodrigues, A.D., Roberts, E.M., Mulford, D.J., Yao, Y., Ouellet, D. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 1997, 25, 623–630.
   PubMed Web of Science ®Google Scholar
• Gorski, J.C., Jones, D.R., Haehner-Daniels, B.D., Hamman, M.A., O’Mara, E.M. Jr, Hall, S.D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998, 64, 133–143.
   PubMed Web of Science ®Google Scholar
• Yew WW, Chau CH, Lee J, Leung CW. Reply to clarithromycin-induced hepatotoxicity (letter). Clin Infect Dis 1995;20:1074.
   Web of Science ®Google Scholar
• Cadranel, J.F., Bachmeyer, C., Pras, V., Bouraya, D., Pourvillain, S., Biour, M., Mougeot-Martin, M. [Acute symptomatic cytolytic hepatitis probably related to clarithromycin]. Gastroenterol Clin Biol 1996, 20, 1034–1035.
   PubMedGoogle Scholar
• Baylor, P., Williams, K. Interstitial nephritis, thrombocytopenia, hepatitis, and elevated serum amylase levels in a patient receiving clarithromycin therapy. Clin Infect Dis 1999, 29, 1350–1351.
   PubMed Web of Science ®Google Scholar
• Guay, D.R., Patterson, D.R., Seipman, N., Craft, J.C. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Saf 1993, 8, 350–364.
   PubMed Web of Science ®Google Scholar
• Wallace, R.J. Jr, Brown, B.A., Griffith, D.E. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993, 16, 215–221.
   PubMed Web of Science ®Google Scholar
• Yew, W.W., Chau, C.H., Lee, J., Leung, C.W. Cholestatic hepatitis in a patient who received clarithromycin therapy for a Mycobacterium chelonae lung infection. Clin Infect Dis 1994, 18, 1025–1026.
   PubMed Web of Science ®Google Scholar
• Brown, B.A., Wallace, R.J. Jr, Griffith, D.E., Girard, W. Clarithromycin-induced hepatotoxicity. Clin Infect Dis 1995, 20, 1073–1074.
   PubMed Web of Science ®Google Scholar
• Sousa, C., Correia, J., Santos, J., Silvestre, F., Bernardo, A. [Cholestatic hepatitis probably induced by clarithromycin]. Gastroenterol Clin Biol 1997, 21, 632–633.
   PubMedGoogle Scholar
• Fox, J.C., Szyjkowski, R.S., Sanderson, S.O., Levine, R.A. Progressive cholestatic liver disease associated with clarithromycin treatment. J Clin Pharmacol 2002, 42, 676–680.
   PubMed Web of Science ®Google Scholar
• Shaheen, N., Grimm, I.S. Fulminant hepatic failure associated with clarithromycin. Am J Gastroenterol 1996, 91, 394–395.
   PubMed Web of Science ®Google Scholar
• Masiá, M., Gutiérrez, F., Jimeno, A., Navarro, A., Borrás, J., Matarredona, J., Martín-Hidalgo, A. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy. Arch Intern Med 2002, 162, 474–476.
   PubMedGoogle Scholar
• Christopher, K., Hyatt, P.A., Horkan, C., Yodice, P.C. Clarithromycin use preceding fulminant hepatic failure. Am J Gastroenterol 2002, 97, 489–490.
   PubMed Web of Science ®Google Scholar
• Tietz, A., Heim, M.H., Eriksson, U., Marsch, S., Terracciano, L., Krähenbühl, S. Fulminant liver failure associated with clarithromycin. Ann Pharmacother 2003, 37, 57–60.
   PubMed Web of Science ®Google Scholar
• Gholson, C.F., Warren, G.H. Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med 1990, 150, 215–216.
   PubMed Web of Science ®Google Scholar
• Carson, J.L., Strom, B.L., Duff, A., Gupta, A., Shaw, M., Lundin, F.E., Das, K. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993, 119, 576–583.
   PubMed Web of Science ®Google Scholar
• Dubois, A., Nakache, N., Raffanel, C., Balmes, J.L. [Acute cholestatic hepatitis after ingestion of roxithromycin]. Gastroenterol Clin Biol 1989, 13, 317–318.
   PubMedGoogle Scholar
• Pedersen, F.M., Bathum, L., Fenger, C. Acute hepatitis and roxithromycin. Lancet 1993, 341, 251–252.
   PubMed Web of Science ®Google Scholar
• Delaforge, M., Jaouen, M., Mansuy, D. Dual effects of macrolide antibiotics on rat liver cytochrome P-450. Induction and formation of metabolite-complexes: a structure-activity relationship. Biochem Pharmacol 1983, 32, 2309–2318.
   PubMed Web of Science ®Google Scholar
• Pessayre, D., Tinel, M., Larrey, D., Cobert, B., Funck-Brentano, C., Babany, G. Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione. J Pharmacol Exp Ther 1983, 224, 685–691.
   PubMed Web of Science ®Google Scholar